We are live on ! Find out more
UBS AM

UBS AM Portfolio holdings

AUM $481B
1-Year Est. Return 26.39%
 

UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.

This Fund
S&P 500
This Quarter Est. Return
+9.49%
1 Year Est. Return
+26.39%
3 Year Est. Return
+93.76%
5 Year Est. Return
+124.47%
10 Year Est. Return
+503.87%
AUM
$191B
AUM Growth
+$12.5B
Cap. Flow
-$1.52B
Cap. Flow %
-0.8%
Top 10 Hldgs %
19.31%
Holding
2,824
New
88
Increased
1,334
Reduced
722
Closed
302

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$498M
2
AME icon
Ametek
AME
+$445M
3
MSFT icon
Microsoft
MSFT
+$432M
4
AAPL icon
Apple
AAPL
+$209M
5
TSLA icon
Tesla
TSLA
+$198M

Sector Composition

Rank Sector Weight
1 Technology 25.01%
2 Healthcare 15.34%
3 Financials 12.73%
4 Consumer Discretionary 9.85%
5 Industrials 8.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
Y
2751
DELISTED
Alleghany Corp
Y
-69,123
Closed -$58M
PING
2752
DELISTED
Ping Identity Holding Corp.
PING
-83,606
Closed -$2.35M
FMTX
2753
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
-18,528
Closed -$370K
GBT
2754
DELISTED
Global Blood Therapeutics, Inc.
GBT
-244,631
Closed -$16.7M
BRG
2755
DELISTED
Bluerock Residential Growth REIT, Inc.
BRG
-53,535
Closed -$1.43M
HNGR
2756
DELISTED
Hanger Inc.
HNGR
-59,172
Closed -$1.11M
DRE
2757
DELISTED
Duke Realty Corp.
DRE
-2,505,131
Closed -$121M
CHNG
2758
DELISTED
Change Healthcare Inc. Common Stock
CHNG
-398,361
Closed -$11M
ABTX
2759
DELISTED
Allegiance Bancshares
ABTX
-16,971
Closed -$707K
CTXS
2760
DELISTED
Citrix Systems Inc
CTXS
-1,010,092
Closed -$105M
EMBK
2761
DELISTED
Embark Technology, Inc. Common Stock
EMBK
-11,555
Closed -$85.9K
TRQ
2762
DELISTED
Turquoise Hill Resources Ltd
TRQ
-8,600
Closed -$254K
NLSN
2763
DELISTED
Nielsen Holdings plc
NLSN
-1,591,541
Closed -$44.1M
FBC
2764
DELISTED
Flagstar Bancorp, Inc. New
FBC
-48,490
Closed -$1.62M
AAWW
2765
DELISTED
Atlas Air Worldwide Holdings, Inc.
AAWW
-10,425
Closed -$996K
OZON
2766
DELISTED
Ozon Holdings PLC American Depositary Shares, each ADS representing one ordinary share
OZON
$0 ﹤0.01%
73,024
BHVN
2767
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
-63,992
Closed -$9.67M

Similar funds

UBS AM's Q4 2022 Portfolio in Review

As of Q4 2022, UBS AM held 2,824 positions worth $191B, up 7% from $178B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

UBS AM's Q4 2022 filing shows 88 new, 1,334 increased, 722 reduced and 302 closed positions. Its largest new stake was Ferguson: 543,379 shares worth $69M. The largest sale was Amgen, an estimated $759M.

By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 26% a quarter earlier, followed by Healthcare and Financials.

  • UBS AM's largest Q4 2022 buy was Ferguson: 543,379 shares worth $69M.
  • UBS AM added most to Amazon in Q4 2022, an estimated $498M increase.
  • UBS AM's biggest Q4 2022 reduction was Accenture, cutting an estimated $529M.
  • UBS AM fully exited Amgen in Q4 2022, selling an estimated $759M.
  • UBS AM's ten largest holdings make up 19% of its $191B portfolio in Q4 2022.
  • UBS AM opened 88 new positions and closed 302 in Q4 2022.
  • UBS AM's portfolio value rose 7% quarter-over-quarter to $191B.

Based on UBS AM's 13F filing for Q4 2022, filed 14 Feb 2023.